当前位置: X-MOL 学术Immune Netw. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines.
Immune Network ( IF 4.3 ) Pub Date : 2021-08-30 , DOI: 10.4110/in.2021.21.e29
Ji Yeun Kim 1 , Seongman Bae 1 , Soonju Park 2 , Ji-Soo Kwon 1 , So Yun Lim 1 , Ji Young Park 1 , Hye Hee Cha 1 , Mi Hyun Seo 1 , Hyun Jung Lee 1 , Nakyung Lee 2 , Jinyeong Heo 2 , David Shum 2 , Youngmee Jee 2 , Sung-Han Kim 1
Affiliation  

There are limited data directly comparing humoral and T cell responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines. We compared Ab and T cell responses after first doses of ChAdOx1 nCoV-19 vs. BNT162b2 vaccines. We enrolled healthcare workers who received ChAdOx1 nCoV-19 or BNT162b2 vaccine in Seoul, Korea. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S1 protein-specific IgG Abs (S1-IgG), neutralizing Abs (NT Abs), and SARS-CoV-2-specific T cell response were evaluated before vaccination and at 1-wk intervals for 3 wks after vaccination. A total of 76 persons, comprising 40 injected with the ChAdOx1 vaccine and 36 injected with the BNT162b2 vaccine, participated in this study. At 3 wks after vaccination, the mean levels (±SD) of S1-IgG and NT Abs in the BNT162b2 participants were significantly higher than in the ChAdOx1 participants (S1-IgG, 14.03±7.20 vs. 6.28±8.87, p<0.0001; NT Ab, 183.1±155.6 vs. 116.6±116.2, p=0.035), respectively. However, the mean values of the T cell responses in the 2 groups were comparable after 2 wks. The humoral immune response after the 1st dose of BNT162b2 developed faster and was stronger than after the 1st dose of ChAdOx1. However, the T cell responses to BNT162b2 and ChAdOx1 were similar.

中文翻译:

单剂量 ChAdOx1 nCoV-19 和 BNT162b2 疫苗诱导的抗体和 T 细胞反应的比较。

直接比较 ChAdOx1 nCoV-19 和 BNT162b2 疫苗的体液和 T 细胞反应的数据有限。我们比较了第一剂 ChAdOx1 nCoV-19 与 BNT162b2 疫苗后的 Ab 和 T 细胞反应。我们在韩国首尔招募了接种 ChAdOx1 nCoV-19 或 BNT162b2 疫苗的医护人员。在接种疫苗前评估了抗严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) S1 蛋白特异性 IgG Abs (S1-IgG)、中和抗体 (NT Abs) 和 SARS-CoV-2 特异性 T 细胞反应接种后 3 周内间隔 1 周。共有 76 人参与了这项研究,其中 40 人注射了 ChAdOx1 疫苗,36 人注射了 BNT162b2 疫苗。接种疫苗后 3 周,BNT162b2 参与者中 S1-IgG 和 NT Abs 的平均水平 (±SD) 显着高于 ChAdOx1 参与者(S1-IgG,14.03±7.20 对 6.28±8.87,p<0.0001;NT Ab,183.1±155.6分别为 116.6±116.2,p=0.035)。然而,2 周后两组 T 细胞反应的平均值具有可比性。第一剂 BNT162b2 后的体液免疫反应比第一剂 ChAdOx1 发展得更快且更强。然而,T 细胞对 BNT162b2 和 ChAdOx1 的反应相似。第一剂 BNT162b2 后的体液免疫反应比第一剂 ChAdOx1 发展得更快且更强。然而,T 细胞对 BNT162b2 和 ChAdOx1 的反应相似。第一剂 BNT162b2 后的体液免疫反应比第一剂 ChAdOx1 发展得更快且更强。然而,T 细胞对 BNT162b2 和 ChAdOx1 的反应相似。
更新日期:2021-08-30
down
wechat
bug